The Regulatory Tailwind Driving 3D Cell Culture’s Next Growth Phase

/in , /by

The 3D cell culture market has been on a strong and sustained growth trajectory, driven primarily by the pharmaceutical and biotechnology industries. Now, a regulatory shift is poised to further amplify that momentum. The FDA Modernization Acts 2.0 and 3.0 have fundamentally rewritten the rules of preclinical drug development, and 3D cell culture products sit squarely at the center of the opportunity. 

What Changed — and Why It Matters 

For over eight decades, the Federal Food, Drug, and Cosmetic Act of 1938 required animal testing as the default gateway to human clinical trials. That changed in December 2022, when President Biden signed the FDA Modernization Act 2.0 into law. The legislation explicitly authorized cell-based assays, organoids, microphysiological systems, and AI-driven computational models as valid evidence in support of an Investigational New Drug (IND) application. 

In December 2025, the Senate passed the FDA Modernization Act 3.0 by unanimous consent. The Act is currently awaiting action in the House before it can be signed into law. Where Act 2.0 granted permission, Act 3.0 provides infrastructure — directing the FDA to establish a formal qualification pathway for New Approach Methodologies (NAMs), including organoids and other innovative platforms. The FDA reinforced this direction with its April 2025 roadmap to phase out routine animal testing, initially targeting monoclonal antibody development. 

Together, these acts represent a structural realignment of the preclinical testing ecosystem — one that directly benefits the 3D cell culture market. 

Why 3D Cell Culture Will Benefit 

3D cell culture products occupy a uniquely favorable position in the new regulatory landscape: 

  • Regulatory readiness. Organoids and spheroids have a well-established scientific track record, replicating in vivo tissue architecture, gene expression, and drug response more accurately than traditional cell culture models. They are among the NAMs most likely to satisfy FDA reviewers in drug safety and efficacy contexts. 
  • Pharmaceutical demand is accelerating. The pharma and biotech sector already dominates demand for 3D cell culture products and is projected to be the fastest-growing end market through the end of the decade. Drug discovery and cancer research are the two largest and most innovative applications. 
  • CROs are a high-upside segment. As pharma sponsors increasingly outsource NAM-based preclinical studies, 3D cell culture demand from contract research organizations stands to grow faster than baseline forecasts suggest. 
  • NIH has added further momentum. In July 2025, the NIH announced that it is prioritizing human-focused research and reducing animal use in research. Among the human-focused methods specifically mentioned were NAMs, including microphysiological systems and organoids. Grant proposals relying exclusively on animal data would no longer be eligible for funding — requiring integration of at least one validated human-relevant method. 

Product Segments Poised for Growth 

The market for 3D cell culture products has seen strong, mid-single digit growth over the past several years, even in the face of funding challenges affecting the biotech industry. The market was estimated to have reached the $1 billion milestone in 2025. Regulatory tailwinds are expected to accelerate growth, with effects most pronounced in: 

  • Organoids and spheroids— organoids are miniaturized, self-organized 3D tissue structures that functionally emulate the architecture and function of organs, making them valuable models for disease research and drug testing. Spheroids are simpler, self-aggregating 3D cell clusters that lack the complex organization of organoids, but mimic the multicellular environment of tumors or tissues, making them widely used for cancer research and drug screening. While many labs conducting basic research opt to make organoids and spheroids in-house, commercially-produced options provide standardized models that are advantageous for customers that are working towards regulatory approval. As formal NAM qualification pathways open under Act 3.0, commercial organoid and spheroid adoption is likely to accelerate, increasing market share for these product segments. 
  • 3D media and matrices — to form and grow the organizational structure of organoids and spheroids, 3D scaffolding mimicking extracellular matrices is required. 3D media and matrices are the consumable backbone of any organoid or spheroid workflow. Every new study represents repeat purchases, making this a reliably recurring and growing segment. However, NAMs-driven demand from the pharma/bio sector will be partially offset by slower growth from the public sector. 
  • 3D cultureware — the largest segment by revenue. Increased preclinical study volumes under the new regulatory framework translate directly into demand for low-attachment microplates, flasks, and dishes. Similar to the market dynamics influencing media and matrices, slower demand from the public sector will offset accelerating growth from pharma/bio. 

The Bottom Line 

The FDA Modernization Acts 2.0 and 3.0 elevate organoids and spheroids from supplementary research tools to first-class regulatory evidence under the new NAMs framework. The 3D cell culture market was already on a strong growth path heading into this decade. With the regulatory environment now firmly aligned behind human-relevant testing methods, growth and innovation for this market is poised to accelerate rapidly. 

Market data sourced from SDi Global Laboratory Consumables 2024, Report 24-003, published November 2024.